drugset / Trial / NCT06712654
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2027-02-28
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AP306 | Unknown | 75 mg | Oral |
| Subject | AP306 | Unknown | 100 mg | Oral |
| Subject | AP306 | Unknown | 125 mg | Oral |
| Subject | AP306 | Unknown | 150 mg | Oral |